New York State Common Retirement Fund
ARQT icon

New York State Common Retirement Fund’s Arcutis Biotherapeutics ARQT Stock Holding History

New York State Common Retirement Fund’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Sell
50,471
-206,157
-80% -$4.8M ﹤0.01% 1626
2026
Q1 		$6.05M Buy
256,628
+213,715
+498% +$5.45M 0.01% 940
2025
Q4 		$1.25M Sell
42,913
-5,757
-12% -$147K ﹤0.01% 1618
2025
Q3 		$917K Hold
48,670
– – ﹤0.01% 1721
2025
Q2 		$682K Hold
48,670
– – ﹤0.01% 1803
2025
Q1 		$761K Buy
48,670
+23,503
+93% +$331K ﹤0.01% 1737
2024
Q4 		$351K Hold
25,167
– – ﹤0.01% 2063
2024
Q3 		$234K Sell
25,167
-18,500
-42% -$183K ﹤0.01% 2217
2024
Q2 		$406K Buy
43,667
+11,972
+38% +$108K ﹤0.01% 2121
2024
Q1 		$314K Buy
31,695
+16,773
+112% +$125K ﹤0.01% 2264
2023
Q4 		$48.2K Sell
14,922
-119
-0.8% -$323 ﹤0.01% 3009
2023
Q3 		$79.9K Buy
15,041
+239
+2% +$2.03K ﹤0.01% 2834
2023
Q2 		$141K Sell
14,802
-9,164
-38% -$102K ﹤0.01% 2649
2023
Q1 		$264K Sell
23,966
-5,985
-20% -$86.6K ﹤0.01% 2478
2022
Q4 		$443K Buy
29,951
+5,367
+22% +$93.8K ﹤0.01% 2370
2022
Q3 		$470K Buy
24,584
+197
+0.8% +$4.46K ﹤0.01% 2353
2022
Q2 		$520K Buy
24,387
+5,434
+29% +$111K ﹤0.01% 2354
2022
Q1 		$365K Buy
18,953
+20
+0.1% +$338 ﹤0.01% 2543
2021
Q4 		$393K Sell
18,933
-62
-0.3% -$1.23K ﹤0.01% 2559
2021
Q3 		$454K Sell
18,995
-4,897
-20% -$112K ﹤0.01% 2518
2021
Q2 		$652K Buy
23,892
+5,692
+31% +$160K ﹤0.01% 2456
2021
Q1 		$527K Hold
18,200
– – ﹤0.01% 2425
2020
Q4 		$512K Buy
18,200
+8,800
+94% +$216K ﹤0.01% 2344
2020
Q3 		$275K Hold
9,400
– – ﹤0.01% 2510
2020
Q2 		$284K Buy
+9,400
New +$272K ﹤0.01% 2490

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

New York State Common Retirement Fund's ARQT Position: Q2 2026 in Review

New York State Common Retirement Fund reduced its Arcutis Biotherapeutics (ARQT) stake by 80% in Q2 2026, selling an estimated $4.8M and leaving 50,471 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1626.

New York State Common Retirement Fund first reported a position in ARQT in Q2 2020 and has held it in 25 quarters since. The position peaked at $6.05M in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • New York State Common Retirement Fund held 50,471 shares of Arcutis Biotherapeutics worth $1.32M as of Q2 2026.
  • New York State Common Retirement Fund sold 206,157 Arcutis Biotherapeutics shares in Q2 2026, an estimated $4.8M.
  • Arcutis Biotherapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #1626 holding.
  • New York State Common Retirement Fund first reported a position in Arcutis Biotherapeutics in Q2 2020 and has held it in 25 quarters since.
  • New York State Common Retirement Fund's Arcutis Biotherapeutics position peaked at $6.05M in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.